Verseon, a Silicon Valley-based drug discovery company now sees itself at this very juncture after building a proprietary AI and physics-driven technology platform to create new drugs atom by atom.
Verseon’s Chief Technology Officer Sangtae Kim, a member of the US National Academy of Engineering, says the platform is far more sophisticated than the ‘AI systems’ of other drug developers, as it enables Verseon to design the entirely new chemical structures needed to fight currently untreatable diseases.
He points out that AI is only as effective as the data available for it to learn from, as shown by issues arising from development of ‘self-driving’ vehicles; in the case of other ‘AI drug discovery systems’ this data comes only from existing drugs and past trial-and-error experiments.
As highlighted by current coverage in Impact Wealth Magazine, Verseon has freed itself from that conventional approach and is bringing much-needed new treatments to market for cancers, heart disease, and other killers. The company is also developing products that slow human aging and boost longevity.
Many market watchers now believe that despite the pharmaceutical industry’s $1 trillion a year patent-protected revenue, its failure-prone trial-and-error drug development process is an increasing impediment to finding badly needed disease treatments.
Verseon’s founders realized that systematic design of completely new drugs requires breakthroughs in molecular-physics modeling to determine how a new chemical structure will bind to a disease-causing protein.
And using its platform, the company has identified multiple new clinical candidates for every one of its programs – a feat unheard of in the pharmaceutical industry.
Verseon’s management team collectively holds over 200 patents and are no strangers to making transformational breakthroughs.
Co-founders Adityo Prakash and Eniko Fodor patented technologies now owned by Intel that power all video streaming today, from Amazon Prime to Zoom. The third Verseon founder, David Kita, developed one of the first bioinformatics platforms that catalyzed the genomics revolution.
And Sangtae Kim – a former VP at major pharma company Eli Lilly and Chair of Purdue’s Chemical Engineering Division – is now driving further enhancement of Verseon’s powerful AI and proprietary data sets.
“Verseon’s platform comprises significant new advances within multiple distinct branches of science,” says Kim. “Any one of these advances would be enthusiastically welcomed by leading practitioners in their respective domains, but collecting them together is virtually unattainable by any other organization. It is by far the most advanced ab initio drug design methodology currently in existence.”
Verseon is currently trialling drugs with remarkably low bleeding risk to treat and prevent heart attacks and strokes in over 400 million patients worldwide. Uncontrolled bleeding is the biggest risk factor associated with current alternatives.
One of the world’s leading cardiologists John Deanfield, University College London’s Professor of Cardiology, commented:
“Verseon’s platelet-sparing anticoagulants…represent an exciting ‘precision medicine’ opportunity for the treatment of a large population of cardiovascular disease patients.”
The company is also developing oral drugs to treat diabetic vision loss in over 154 million patients, treatments for coronaviruses and influenza, and three different programs to fight cancer – one of the world’s biggest killers.
All of these are part of a fast-growing drug pipeline of 16 candidate drugs across eight programs.
Pfizer’s former SVP of R&D Strategy Robert Karr commented: “Verseon’s platform is finally ushering in the age of systematic drug discovery.”
To advance global health, Verseon International Corporation has created a superior and more scalable process for designing and developing new drugs addressing currently untreatable or poorly treated conditions.
Its drug development platform incorporates fundamental advances in molecular modeling, directed synthesis, integrated translational research, and advanced AI to develop drug compounds never before synthesized, and virtually impossible to find using conventional methods.
Verseon is a clinical stage company with a growing pipeline that currently includes seven drug programs in the areas of anticoagulation, diabetic retinopathy, hereditary angioedema, oncology, and metabolic disorders.
The company was founded in 2002 by Adityo Prakash (CEO), Eniko Fodor (COO), and David Kita (VP R&D) who hold over 100 patents between them.